Journal of Cancer Prevention

eISSN 2288-3657
pISSN 2288-3649

Summary of immunopreventive agents

Agent Target Cancer preventive effect References
HPV vaccine Cervarix, a bivalent vaccine, targets HPV 16/18Gardasil, a quadrivalent vaccine, targets HPV 6/11/16/18Gardasil 9, a 9-valent vaccine, targets 9 types of HPV Prevents HPV-related cancers, including cervical, anal, vulvar, vaginal, penile, and oropharyngeal cancer 38, 43-43
HBV vaccine HBV Prevents HBV-related liver cancer 44-49
MUC1 vaccine MUC1 antigen MUC1 vaccine produced strong immune response in patients with intestinal polyps and in individuals at high risk for colon cancer in Human clinical trials 54-57
HER2 vaccine HER2 antigen Human clinical trials showed DCIS remission, long-term production of Her2 antibodies, and lost expression of Her2 58, 59
Immune checkpoint inhibitors (CLTA-4, PD-1, PD-L1 antibody) Immune checkpoint proteins (CLTA-4, PD-1, PD-L1) Preclinical mouse models showed anti-PD-1 treatment significantly prevented malignant progression of oral premalignant lesions 64-68
A case report showed anti-PD-1 inhibited the development of new neoplasm in a Lynch syndrome patient 37

HPV, human papillomavirus; HBV, hepatitis B virus; HER2, human epidermal growth factor receptor 2; DCIS, ductal carcinoma in situ; CLTA-4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed cell death protein-1; PD-L1, programmed death ligand-1.

J Cancer Prev 2020;25:127~135
© J Cancer Prev
Copyright © Korean Society of Cancer Prevention. All Rights Reserved. / Powered by INFOrang Co., Ltd